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Abbreviations
Aβ  Amyloid β
ASC  Apoptosis speck-like protein containing a  
caspase-recruitment domain
BMDM  Bone marrow-derived macrophage
FTIR  Fourier-transformed infrared spectroscopy
IL-1β  Interleukin-1β
LPS  Lipopolysaccharide
NF-κB  Nuclear factor-kappa B
NLR  Nucleotide oligomerization domain-like receptor
NLRP3  NLR, pyrin domain containing 3
PMA  Phorbol 12-myristate 13-acetate
PRR  Pattern-recognition receptor
TEM  Transmission electron microscopy
ThT  Thioflavin T
TLR  Toll-like receptor
TNF-α  Tumor necrosis factor-α
Introduction
Amyloidoses are a set of human diseases characterized 
by the deposition of aggregated proteins in a variety of 
tissues and organs. To date, over 20 different proteins have 
been associated with human amyloidoses [1]. Strikingly, 
despite their different sequences, all these proteins form 
similar deposits sharing the same morphology, consisting 
of unbranched fibrils [2]. This typical fibrillar morphology 
arises from a common structural architecture known as cross-β 
structure, which consists of ordered pileups of β-sheets, with 
β-strands perpendicular to the fibril axis [3]. In neurodegen-
erative amyloidoses such as Alzheimer’s and Parkinson’s 
diseases [4, 5], the presence of amyloid deposits in the brain 
triggers uncontrolled neuroinflammation via activation of 
the brain resident immune cells (microglia) [6], a process 
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which actively contributes to disease progression. The pres-
ence of inflammatory markers such as activated microglia 
or elevated levels of proinflammatory cytokines around the 
amyloid aggregates is a known feature of many amyloi-
doses. In a growing number of cases, such as Alzheimer’s 
disease [7], Parkinson’s disease [8], or type II diabetes 
[9], it has been shown that the aggregated protein itself 
triggers an inflammatory response, demonstrating that the 
inflammation associated with these diseases arises, at least 
in part, from the presence of the amyloid aggregates them-
selves. Understanding the molecular mechanisms by which 
amyloid deposits trigger inflammation might therefore pro-
vide new clues to develop therapeutic strategies to combat 
these important diseases.
Many cytokines are expressed by immune cells in the 
brain of patients suffering from neurodegenerative diseases. 
One of them, interleukin-1β (IL-1β), is critical for orches-
trating the inflammatory response [10], by inducing fever, 
recruiting immune cells, and regulating cell death. IL-1β 
production involves a two-step mechanism [10]. The first 
step consists in the induction of the IL-1β inactive precursor 
(pro-IL-1β) expression through activation of the tran-
scription factor NF-κB. Generally, this step is reached by 
activating a Toll-like receptor (TLR), a subgroup of the 
pattern recognition receptors (PRRs) used by the innate 
immune system to detect pathogens and endogenous dan-
ger signals [11]. The second step requires a second signal, 
independent from the first one, which induces the assembly 
of large multiprotein complexes called inflammasomes, 
which finally process pro-IL-1β into mature IL-1β. Inflam-
masomes are generally composed of three elements: 
(1) a nucleotide oligomerization domain-like receptor 
(NLR), which senses the activating signal, (2) pro-caspase-1, 
which cleaves pro-IL-1β, and (3) in most cases, the protein 
ASC (apoptosis speck-like protein containing a caspase-
recruitment domain), which bridges pro-caspase-1 and the 
NLR [12]. Upon activation of the NLR, inflammasome 
elements oligomerize to form large complexes mediating 
cleavage of pro-IL-1β.
To date, three amyloid aggregates have been shown 
to induce the secretion of IL-1β through inflammasome 
activation: the amyloid-β peptide (Aβ) [7], superoxide 
dismutase 1 (SOD1) [13], and the islet amyloid polypeptide 
(IAPP) [9, 14]. However, the exact nature of the aggre-
gates that actually activate the inflammasome is confusing, 
as the structure of the incriminated species has not been 
investigated.
Lysozyme systemic amyloidosis is a non-neuropathic 
hereditary disorder caused by the deposition of amyloid 
fibrils made of mutational variants of lysozyme [15]. Accu-
mulation of these insoluble aggregates in kidney, liver, or 
spleen is usually slow, but ultimately leads to organ failure 
and is always fatal. The mechanism of amyloid fibril 
formation by lysozyme has been extensively studied, and 
is increasingly well understood at the molecular level [16]. 
However, the effects generated by these aggregates at the 
cellular level are poorly understood.
Here, we analyze the cellular responses induced by 
lysozyme amyloid fibril administration to immune cells, 
and focus mainly on pro-inflammatory cytokine secretion. 
We show that lysozyme fibrils activate TLR2 and NLRP3 
(NLR, pyrin domain containing 3), identifying two innate 
immune receptors that may be involved in the pathology 
of systemic non-neuropathic amyloidoses. Monomers and 
non-fibrillar aggregates of lysozyme, however, fail to stimu-
late TLR2 and NLRP3. In these species, lysozyme adopts 
different conformations than in fibrils, lacking the charac-
teristic cross-β structural motif, suggesting that lysozyme 
fibril-induced inflammation is based around their intrinsic 
structure. Since fibrils of other bacterial and endogenous 
proteins trigger immunological responses, our observations 
suggest that the cross-β sheet structure found in all amy-
loid fibrils may constitute a generic pattern sensed by innate 
receptors.
Materials and methods
Reagents and cell strains
Human embryogenic kidney cells (HEK 293) were obtained 
from ATCC (Manassas, VA, USA). THP1 cells (human acute 
monocytic leukemia cell line) were obtained from HPA 
Cultures (Salisbury, United Kingdom). THP1-XBlue cells, 
ASC-deficient and NLRP3-deficient THP1 cells, Normocin, 
Zeocin, HygroGold, Ultrapure flagellin from S. typhimu-
rium, FSL-1, Ultrapure standard lipopolysaccharide (LPS) 
from E. coli 0111:B4, Pam3CysSerLys4 (Pam3CSK4), 
poly(dA:dT) (provided complexed with the cationic lipid 
Lyovec to facilitate its uptake) and anti-TLR antibodies were 
from InvivoGen (San Diego, CA, USA). RPMI (Roswell 
Park Memorial Institute) and DMEM (Dulbecco’s modi-
fied Eagle’s medium) media, heat-inactivated fetal bovine 
serum (FBS), L-glutamine, sodium pyruvate, penicillin, 
streptomycin, and β-mercaptoethanol were from Lonza 
(Basel, Switzerland). Bay 11-8072, Phorbol 12-myristate 
13-acetate (PMA) and thioflavin T were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), and z-VAD-fmk was 
from Biovision (Mountain View, CA, USA). The horserad-
ish peroxidase-conjugated secondary polyclonal antibody to 
rabbit was from Cell Signaling Technology (Danvers, MA, 
USA). The human IL-1β polyclonal antibody and ELISA 
kits were from R&D Systems (Minneapolis, MN, USA). 
The human caspase-1 polyclonal antibody and the horserad-
ish peroxidase-conjugated secondary polyclonal antibody to 
sheep were from Abcam (Cambridge, United Kingdom).
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Preparation of lysozyme samples
Human lysozyme was expressed in Pichia pastoris, purified 
and stored lyophilized as described previously [17].
Monomer preparation
The lyophilized protein was just resuspended in water 
at the desired concentration (usually around μM).
Formation of fibrils
Stock solutions of lysozyme were prepared in 0.1 M 
tri-sodium citrate buffer (pH 5.5), filtered (0.22-μm pore 
size) and diluted to a final concentration of 0.1 mg/ml in 
0.1 M tri-sodium citrate buffer (pH 5.5) containing 8 M 
urea. Samples (24 × 1.5 ml) were incubated at 60 °C, with 
stirring, in a Cary100 spectrophotometer equipped with a 
Peltier-controlled holder (Varian). Protein aggregation was 
monitored through changes in turbidity at 600 nm. Under 
these conditions, the aggregation was completed within 
~1 h. Fibril suspensions were centrifuged (17,100 × g for 
30 min) and the pellets subjected to three washing cycles in 
1.5 ml milliQ water. Between each cycle, the suspensions 
were centrifuged and the supernatants discarded to remove 
soluble protein, buffer, and urea. The pellet obtained after 
the last cycle was resuspended in milliQ water at a concen-
tration of ~2 mg/ml and kept at 4 °C until further analysis.
Formation of amorphous aggregates
Amorphous aggregates were formed as previously described 
[18] by incubating lysozyme (0.3 mg/ml) overnight at 42 °C 
in phosphate buffered saline (PBS, pH 7.5) containing 
20 mM DTT. The aggregate suspension was centrifuged 
(17,100 × g for 30 min) and the pellet subjected to three 
washing cycles in milliQ water. Between each cycle, the 
suspension was centrifuged and the supernatant discarded to 
remove soluble protein and buffer. The pellet obtained after 
the last cycle was resuspended in milliQ water at ~2 mg/ml 
and kept at 4 °C until analyzed.
To determine the amount of fibrillar and amorphous 
aggregates, the amount of lysozyme present in the super-
natant of each washing step was subtracted from the total 
amount of protein engaged in the aggregation process. 
Protein concentration in each supernatant was determined 
by measuring the absorbance at 280 nm using a molar 
extinction coefficient of 37,689 M−1 cm−1.
Cell culture
THP1 cells were cultured in RPMI 1640 supplemented 
with 10 % heat-inactivated FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 50 U/ml penicillin, 50 μg/ml strepto-
mycin, and 50 μM β-mercaptoethanol. ASC-deficient and 
NLRP3-deficient THP1 cells were cultured in the same 
medium, but supplemented with Normocin and HygroGold. 
After stimulation, cell culture supernatants were collected 
and assayed for human IL-1β or human TNF-α (tumor 
necrosis factor-α) by ELISA (enzyme-linked immunosorb-
ent assay) according to the manufacturer’s instructions. 
THP1-XBlue cells, which express a secreted embryonic 
alkaline phosphatase (SEAP) when NF-κB is activated, 
were cultured in the same medium as THP1 cells, comple-
mented with 100 μg/ml Normocin and 200 μg/ml Zeocin. 
The phosphatase produced by THP1-XBlue cells upon incu-
bation with NF-κB activators was detected using the Quanti 
Blue medium (InvivoGen, San Diego, CA, USA), accord-
ing to the manufacturer’s instructions. For experiments with 
priming, THP1 cells were first resuspended in fresh medium 
(5 × 105 cells/ml) containing 0.5 μM PMA the day prior to 
stimulation, seeded in 24-well plates (5 × 105 cells/well), 
and incubated for 3 h at 37 °C. The medium was then 
exchanged for PMA-free medium and the cells were further 
incubated overnight. The next day, cells were washed with 
serum-free medium and incubated for 6 h with lysozyme 
samples (10 μM unless stated otherwise) in serum-free 
medium. When specified, the stimulation was done in the 
presence of 130 nm KCl, 20 μM z-VAD-fmk or 20 μM 
Bay 11-7082. For experiments without priming, THP1 cells 
were resuspended in fresh medium (final concentration 
6 × 105 cells/ml), plated in 96-well plates (105 cells/well) 
or 24-well plates (5 × 105 cells/well) and directly incubated 
for 6 h with either lysozyme monomers, fibrils, or amor-
phous aggregates (5 μM unless stated otherwise), ultrapure 
LPS (5 ng/ml), Pam3CSK4 (1 ng/ml), FSL-1 (100 ng/ml), 
or ultrapure flagellin (100 ng/ml) in fresh medium. When 
anti-TLR antibodies and Bay 11-7082 were used, THP1 
cells were incubated for 1 h with the antibodies (20 μg/ml) 
or Bay 11-7082 (20 μM) prior to the addition of activators.
Primary bone marrow-derived macrophages (BMDMs) 
were isolated from femurs and tibiae of NLRP3−/− C57BL/6 
mice or their WT littermates and cultured in BMDM medium 
in Petri dishes. BMDMs were cultured in DMEM supple-
mented with 10 % (v/v) FBS, 8 mM L-glutamine, 10 μg/ml 
gentamicin, and 20 % (v/v) of L929-conditioned medium 
(supernatant taken from L929 cells, a murine M-CSF-pro-
ducing cell line). Once cells had become confluent after 
approximately 8–10 days, they were harvested by scrap-
ing and seeded in 96-well (5 × 105 cells/ml - 200 μl/well) 
plates with fresh medium. They were then incubated at 
37 °C - 5 % CO2 overnight to allow the cells to adhere to the 
plate. Cells were then primed for 3 h with 100 ng/ml LPS 
or medium (unprimed cells), and stimulated for 21 h with 
the ligands. After stimulation, cell culture supernatants were 
collected and assayed for mouse IL-1β or mouse TNF-α by 
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ELISA using the BD OptEIA sets from BD Biosciences 
(San Diego, CA, USA) or DuoSet ELISA kits from R&D 
Systems, respectively, according to the manufacturer’s 
instructions.
HEK 293 cells were maintained in DMEM supple-
mented with 10 % FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 μg/ml streptomycin. After 48 h, 
cells were stimulated for 6 h with the different lysozyme 
species, UltraPure LPS (100 ng/ml) or Pam3CSK4 (200 ng/ml) 
diluted in serum-free DMEM. Cells were then washed 
with PBS and then lysed with passive lysis buffer 
(Promega, Madison, WI, USA). Luciferase and Renilla 
activity were then quantified on a FLUOStar Omega plate 
reader (BMG Labtech, Ortenberg, Germany) using lucif-
erase reagent (20 mM Tricine, 2.67 mM MgSO4.7H2O, 
0.265 mM (MgCO3)4Mg(OH)2.5H2O, 0.1 mM EDTA (ethyl-
enediaminetetraacetic acid), 33.3 mM DTT (dithiothreitol), 
530 μM ATP (adenosine-5′-triphosphate), 270 μM acetyl 
CoEnzyme A (lithium salt), 470 μM Luciferin (Biosynth, 
Staad, Switzerland), pH 7.8, dissolved two times in water 
before use) or coelenterazine reagent (coelenterazine (Bio-
synth, Staad, Switzerland) dissolved in ethanol at 1 mg/ml 
diluted 500 times in PBS before use). Luciferase lumines-
cence intensity was normalized to Renilla luminescence 
intensity and data were expressed as fold induction as com-
pared to non-induced control.
Cell transfection
Cells were transfected as previously described [19]. Cells 
were seeded at 4 × 104 cells/ml in 96-well plates and tran-
siently transfected 3 days later. For TLR4 activation, expres-
sion vectors containing cDNA encoding TLR4, MD2, and 
CD14 (1 ng/well of each), a NF-κB transcription reporter 
vector encoding firefly luciferase (5 ng/well pNF-κB-luc 
from Clontech, Saint-Germain-en-Laye, France), and a 
constitutively active reporter vector encoding Renilla lucif-
erase (5 ng/well phRG-TK; Promega, Madison, WI, USA), 
together with empty vector to ensure that an optimal amount 
of DNA was mixed with jetPEI (Polyplus transfection, New 
York, NY, USA) according to the manufacturer’s instruc-
tions. For TLR2 activation, expression vectors coding for 
TLR2 with and without CD14 were transfected with reporter 
plasmids and empty plasmids.
Western blots
Cell supernatants were concentrated using 10-kDa cut-off 
Amicon filter devices (Microcon from Millipore, Billerica, 
MA, USA), resuspended in Laemmli buffer, and heated at 
95 °C for 5 min. Samples were separated by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) 
(14 % acrylamide) and subsequently transferred onto 
nitrocellulose membranes, which were then blocked for 1 h 
in 5 % non-fat dry milk in Tris buffered saline (TBS)/Tween 
20 buffer (10 mM Tris/HCl, pH 8, 150 mM NaCl, 0.0625 % 
Tween 20). Membranes were then incubated with either the 
goat polyclonal anti-human IL-1β antibody (0.2 μg/ml) or the 
rabbit polyclonal anti-human caspase-1 antibody (2 μg/ml). 
Detection was carried out using either horseradish peroxi-
dase-conjugated anti-goat antibody (1:2,000) or horseradish 
peroxidase-conjugated anti-rabbit antibody (1:1,000) and 
the Supersignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology, Rockford, IL, USA). Pictures were 
recorded and analyzed using the ImageQuant 400 gel 
imager and ImageQuant TL software (GE Healthcare, Little 
Chalfont, United Kingdom).
Dot blots
Amounts of 5 μl and 10 μl of lysozyme monomers, fibrils, 
and amorphous aggregates (1 mg/ml) were spotted on 
three nitrocellulose membranes (Millipore, Billerica, MA, 
USA). These membranes were incubated overnight at 4 °C 
in TBS buffer (pH 7.5) supplemented with 3 % ovalbumin 
(Sigma-Aldrich (St. Louis, MO, USA)). After three washing 
steps in TBS with 0.001 % Tween 20 (TBST), the mem-
branes were then respectively incubated for 1 h at room 
temperature with either (1) a 1:1,000 dilution of polyclonal 
rabbit anti-lysozyme antiserum (Washington Biotechnology 
Inc., Columbia, MD, USA), (2) a 1:5,000 dilution of the 
rabbit anti-oligomers A11 antibody (gift from Dr. C. Glabe, 
UC Irvine, CA, USA) and (3) a 1:5,000 dilution of the anti-
fibrils OC antibody (gift from Dr. C. Glabe). After three 
washing steps in TBST, membranes were incubated with an 
alkaline phosphatase-conjugated goat anti-rabbit IgG (Bio-
Rad, Hercules, CA, USA) (dilution 1:3,000 1 % bovine 
serum albumin in TBST) for 1 h at room temperature. Col-
orimetric detection of alkaline phosphatase activity was 
performed using 5-bromo-4-chloro-3-indonyl-phosphatase 
in conjugation with nitro blue tetrazolium.
Fourier-transformed infrared spectroscopy (FTIR)
Infrared spectra were recorded on an Equinox 55 infrared 
spectrophotometer (Bruker Optics) equipped with a Golden 
Gate reflectance accessory (Specac). The internal reflection 
element was a diamond crystal (2 × 2 mm) with an aper-
ture angle of 45° that yielded a single internal reflection. 
A total of 128 accumulations were performed to improve the 
signal-to-noise ratio. The spectrometer was continuously 
purged with dried air. Spectra were recorded at a resolu-
tion of 2 cm−1. Then 2 μl (~10 ng) of lysozyme samples 
were spread on the diamond surface and excess water was 
removed under N2 flow. The self-deconvolution was carried 
out using a Lorentzian line shape for the deconvolution and 
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a Gaussian line shape for the apodization. To quantify the 
area of the different components of amide I revealed by the 
self-deconvolution, a least-squares iterative curve fitting 
was performed to fit a mixture of Gaussian and Lorentzian 
line shapes to the spectrum between 1,700 and 1,600 cm−1. 
Prior to curve fitting, a straight baseline passing through the 
ordinates at 1,700 and 1,600 cm−1 was subtracted. To avoid 
introducing artifacts due to the self-deconvolution proce-
dure, the fitting was performed on the non-deconvoluted 
spectrum. The proportion of a particular structure was com-
puted to be the sum of the area of all fitted bands having 
their maximum in the frequency region where that structure 
occurs divided by the area of all Gaussian/Lorentzian bands 
having their maximum between 1,700 and 1,600 cm−1 
[20, 21].
Thioflavin T binding
 A protein sample of 5 μl (appropriately diluted to reach a 
final protein concentration of 0.8 μM) was added to 1.5 ml 
of a 50 μM thioflavin T (ThT) solution (prepared in 10 mM 
sodium phosphate buffer, 150 mM NaCl, pH 7). ThT binding 
was then monitored by exciting the sample at 440 nm (slit 
width 5 nm) and recording the emission fluorescence spec-
trum from 450 to 600 nm (at a rate of 1,200 nm/min, slit 
width 5 nm). Measurements were carried out at 25 °C with 
stirring, on a Cary Eclipse spectrofluorometer equipped with 
a Peltier-controlled holder (Varian, Mulgrave, Australia). For 
each sample, 20 fluorescence emission spectra were recorded, 
averaged, and corrected for background fluorescence of the 
ThT solution alone. The measurements were carried out at 
least in triplicate, and the averages were represented.
Transmission electron microscopy (TEM)
Samples (10 μl) at a concentration of 0.2 mg/ml were left 
for 2 min on carbon-coated 400-mesh copper grids before 
being stained for 1 min with 2 % uranyl acetate. The grids 
were then washed once with 2 % uranyl acetate (w/v) and 
finally, three times with milliQ water. Images were recorded 
on a Philips CEM100 transmission electron microscope 
operating at 100 kV.
Results
Characterization of two morphologically different 
lysozyme aggregates
Fibrils were prepared by incubating wild-type (WT) human 
lysozyme in acidic conditions (Materials and methods). The 
fibrillar nature of the aggregated species formed under these 
conditions was confirmed by negative stained transmission 
electron microscopy (TEM) (Fig. 1a, left). The structures 
observed include some well-resolved isolated fibrils (diam-
eter of ~13.5 nm) although most fibrils appear to be incorpo-
rated into large bundles (diameter of ~150 nm). Such fibrils 
and ribbon structures have previously been observed with 
several amyloidogenic variants of lysozyme [22] and the 
wild-type protein [23].
In order to investigate the role of fibril structure in their 
inflammatory properties, we also prepared non-fibrillar 
lysozyme aggregates using reducing conditions [18]. TEM 
images of these aggregates (Fig. 1a, right) displayed a 
clearly different morphology to our standard fibrillar prepa-
ration. While lysozyme fibrils formed typical unbranched 
fibrils, aggregates prepared under reducing conditions 
assembled into larger amorphous aggregates of irregular 
shape, referred to as “amorphous aggregates” from now on 
in this paper.
The different morphologies of amorphous and fibrillar 
aggregates reflect distinct conformations of the polypeptide 
chain
The structure of our aggregates was examined by Fourier- 
transformed infrared spectroscopy (FTIR), a method 
particularly well suited to the study of proteins and pro-
tein aggregates [20, 24]. Amide I, a specific region of the 
infrared spectrum of proteins located between 1,600 and 
1,700 cm−1, is very sensitive to the secondary structure of 
proteins [20]. Deconvolution and curve-fitting of this region 
gives the percentage of content in each secondary structure 
type, as listed in Table 1. For fibrils and monomers, these 
percentages are in good agreement with those obtained in a 
previous work [23].
The monomeric sample (Fig. 1b, pink) exhibits a mix-
ture of different structures, but mainly contains α-helical 
and random structures (58 %), as shown by the single maxi-
mum around 1,650 cm−1. Lysozyme fibrils have the typical 
spectrum of amyloid fibrils: the major peak located at 
1,625 cm−1 (Fig. 1b, cyan) is the signature of β-sheets, and 
the absence of a concomitant absorption peak at 1,695 cm−1 
demonstrates that these β-sheets are parallel [25, 26], the 
relative orientation usually adopted by β-strands in the generic 
cross-β architecture of amyloid fibrils [27, 28]. Random and 
helical structures (1,650 cm−1) are detected, as well as loops 
and turns (1,670 cm−1), but to a lesser extent than in the two 
other conformations. The spectrum of amorphous aggregates 
(Fig. 1b, blue) does not show the features present in the fibril 
spectrum. First, their β-sheet content is considerably reduced 
as compared with fibrils, dropping from 79 to 44 % with a 
concomitant substantial enrichment in the other structures 
(Table 1). Secondly, the β-sheets found in amorphous aggre-
gates are different from those of fibrils: the spectrum shows, 
in addition to the 1,625 cm−1 band, a peak at 1,695 cm−1 
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(Fig. 1b, blue, arrow). The simultaneous presence of these 
two bands is the spectral signature of antiparallel β-sheets 
[29–31]. For further visualization of this antiparallel spectral 
signature, we examined the second derivative of the spectra 
(Fig. 1c). The concomitant presence of the 1,625 and 
1,695 cm−1 peaks (arrows) appears very clearly with amor-
phous aggregates (Fig. 1c, blue), while the lysozyme fibril 
spectrum only have the 1,625 cm−1 peak (Fig. 1c, cyan).
These structural differences between fibrillar and amor-
phous aggregates were further supported by measuring the 
fluorescence of ThT, a dye which specifically fluoresces 
in the presence of the β-pleated sheet conformation of 
amyloid fibrils [32]. ThT fluorescence was not amplified in 
the presence of amorphous aggregates (Fig. 1d, dashed), nor 
in the presence of monomers (Fig. 1d, dotted), whereas a 
strong fluorescence increase was detected in the presence 
of lysozyme fibrils (Fig. 1d, solid), confirming the fibrillar 
nature of these aggregates.
In addition, the conformation-dependent fibril-specific 
OC [33] antibody did not recognize amorphous aggre-
gates, although it clearly detected lysozyme fibrils (Fig. 1e). 
Finally, the conformational A11 antibody raised against 
oligomers [34] did not recognize any lysozyme aggregates 
(Fig. 1e), ruling out any oligomeric contamination.
Taken together, these results provide strong evidence that 
while lysozyme fibrillar aggregates harboring high β-sheet 
Fig. 1  Characterization of lysozyme species. a Negative stained 
TEM images of lysozyme fibrils (left) and amorphous aggre-
gates (right). The scale bar represents 500 nm. b Infrared spec-
trum of lysozyme monomers (pink), amorphous aggregates (blue), 
and fibrils (cyan). Spectra were scaled for identical Amide I area 
(1,711–1,590 cm−1). The 1,625 cm−1 peak (solid line) is characteris-
tic of β-sheets, and the presence of an additional peak at 1,695 cm−1 
(arrow) is the spectral signature of antiparallel β-sheets. c 2nd deriva-
tive of the infrared spectra shown in b (same color code). For better 
visualization, those derivatives have been reversed. The arrows point 
to the 1,625 and 1,695 cm−1 peaks. d ThT fluorescence assay in the 
presence of 0.8 μM of either lysozyme fibrils (solid line), monomers 
(dotted line), or amorphous aggregates (dashed line) (λex: 440 nm). 
e Dot blot of lysozyme monomers (left), fibrils (middle), and amor-
phous aggregates (right) using the fibril-specific OC antibody (upper 
panel) or the oligomer-specific A11 antibody (lower panel)
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content with a parallel relative orientation of the β-strands 
adopt the typical cross-β architecture found in all amyloid 
fibrils, amorphous aggregates do not present this character-
istic architecture. Moreover, they highlight that the differ-
ent morphologies adopted by these two types of lysozyme 
aggregates are associated with fundamentally different 
molecular conformations of the protein.
Fibrillar aggregates of lysozyme, but not amorphous  
aggregates, trigger IL-1β secretion
To investigate whether lysozyme aggregates were able to 
induce inflammatory responses, we incubated the human 
monocytic THP1 cell line with our lysozyme samples and 
tested their ability to induce the release of mature IL-1β. 
To differentiate cells into macrophages and ensure strong 
expression of pro-IL-1β, THP1 cells were first primed 
with PMA [12, 35]. Incubation with lysozyme fibrils 
then resulted in the secretion of high levels of IL-1β in a 
concentration-dependent manner (Fig. 2a), similarly to 
ATP or nigericin (Fig. 2a), two compounds that trigger pro-
IL-1β processing through the NLRP3 inflammasome [36]. 
Non-aggregated lysozyme and amorphous aggregates, in 
contrast, did not induce any IL-1β secretion, even at the 
highest concentration (Fig. 2a). Immunoblot analysis con-
firmed the presence of cleaved IL-1β in cell supernatants 
when incubated with lysozyme fibrils but not with mono-
mers or amorphous aggregates (Fig. 2b).
IL-1β production occurs through activation of caspase-1, 
the effector component of inflammasomes [12, 37]. Pro-
caspase-1 cleavage was indeed induced by lysozyme fibrils 
in a concentration-dependent manner, while no cleaved 
caspase-1 was detected following incubation with the unag-
gregated protein or with amorphous aggregates (Fig. 2b). 
Finally, incubation of LPS-primed mouse primary bone 
marrow-derived macrophages (BMDMs) with fibrillar 
lysozyme also led to a concentration-dependent produc-
tion of IL-1β. Like in THP1 cells, lysozyme monomers and 
amorphous aggregates did not induce any cytokine secretion 
(Fig. 2c).
Fig. 2  Lysozyme fibrils, but not amorphous aggregates, induce 
IL-1β secretion. a, b PMA-primed THP1 cells were incubated for 
6 h with the indicated amounts of either lysozyme fibrils, amorphous 
aggregates or monomers, ATP (2 mM) or Nigericin (10 μM). Cell 
supernatants were analyzed by ELISA (a) or immunoblotting for IL-1β 
(b, upper panel) and for activated caspase-1 (casp-1) (b, lower panel); 
c LPS-primed mouse BMDMs were stimulated for 21 h with the indi-
cated amounts of either lysozyme fibrils, monomers, or amorphous 
aggregates, or transfected with poly(dA:dT) (5 μg/ml), and cell 
supernatants were analyzed for IL-1β by ELISA. n = 3, represented 
as mean ± standard deviation (SD)
Table 1  Secondary structure content of lysozyme in the three 
different states
The proportions of each secondary structure have been calculated 
from spectra shown in Fig. 1b, by deconvolution and curve fitting of 









β-sheets 15 79 44
α-helix/random 58 14 29
Loops/turns 28 7 28
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Fibrillar lysozyme activates the NLRP3 inflammasome
Further confirming the involvement of inflammasome, 
fibril-induced IL-1β secretion and caspase-1 activation were 
inhibited by KCl, which prevents the potassium efflux that 
is essential for inflammasome activation [38] and by the 
pan-caspase inhibitor z-VAD-fmk (Fig. 3a, b). Among the 
five inflammasomes described to date, the NLRP3 inflam-
masome is the most likely candidate for fibril-induced IL-1β 
secretion, because other aggregated and particulate substrates 
have been shown to activate this complex [39]. Supporting 
this assumption, Bay 11-7082, a compound known to block 
NLRP3 [40] abrogated fibril-induced IL-1β secretion and 
caspase-1 activation (Fig. 3a, b). In ASC-deficient THP1 
cells (THP1-DefASC), where ASC was knocked down by 
RNA interference, no cleaved IL-1β was produced in the 
presence of lysozyme fibrils (Fig. 3c, middle panel), show-
ing that this adaptor protein is required for inflammasome 
activation. THP1-DefNLRP3 also did not produce IL-1β in 
response to fibrillar lysozyme (Fig. 3c, right panel), unam-
biguously demonstrating that the NLRP3 inflammasome is 
responsible for lysozyme fibril-mediated IL-1β secretion. As 
Fig. 3  Lysozyme fibrils activate the NLRP3 inflammasome. a, b 
PMA-primed THP1 cells were incubated for 6 h with 5 μM lysozyme 
fibrils in the presence or absence of either KCl (130 nM), the pan-
caspase inhibitor z-VAD-fmk (20 μM), or the NLRP3 inhibitor 
Bay 11-7082 (20 μM). Cell supernatants were analyzed for IL-1β 
by ELISA (a) and immunoblotting (b, upper panel) or for activated 
caspase-1 (casp-1) (b, lower panel); c PMA-primed WT, ASC-
deficient (Def-ASC) and NLRP3-deficient (Def-NLRP3) THP1 cells 
were incubated for 6 h with ATP (2 mM) or the indicated amounts 
of lysozyme fibrils, and IL-1β was quantified by ELISA in the cell 
supernatant; d LPS-primed BMDMs from WT (black bars) or 
NLRP3 KO (grey bars) mice were stimulated for 21 h with the indi-
cated amounts of either lysozyme fibrils or monomers, or transfected 
with poly(dA:dT) (5 μg/ml), and cell supernatants were analyzed for 
IL-1β by ELISA. n = 3, mean ± SD
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expected [36], ATP-induced IL-1β release was also depend-
ent on ASC and NLRP3 proteins (Fig. 3c).
Again, similar results were obtained in primary BMDMs 
(Fig. 3d): lysozyme fibrils induced a concentration-
dependent secretion of mature IL-1β from LPS-primed WT 
BMDMs, but not from NLRP3 knockout BMDMs (Fig. 3d).
Fibrillar aggregates of lysozyme, but not amorphous  
aggregates, induce IL-1β secretion from non-primed cells
The production of IL-1β is a two-step process with the 
first step requiring the synthesis of pro-IL-1β. In vitro, 
the first signal is generally induced by priming cells with 
compounds such as PMA or LPS [12, 35] (Figs. 2, 3). In 
vivo, it is unclear which signals prime cells for inflamma-
some activation. In amyloidogenic diseases, we hypoth-
esized that amyloid fibrils may themselves induce cellular 
priming. To test this hypothesis, we added lysozyme fibrils 
to unprimed THP1 cells and mouse primary macrophages. 
Lysozyme fibrils still induced concentration-dependent 
secretion of IL-1β from THP1 cells (Fig. 4a) and mouse 
primary BMDMs (Fig. 4e) albeit at lower levels than seen 
in primed cells (Fig. 2). Conversely, lysozyme monomers 
and amorphous aggregates did not induce any secretion of 
IL-1β in unprimed THP1 cells or BMDMs (Fig. 4a, e), as 
expected since they both failed to activate the inflamma-
some in primed cells (Fig. 2).
Transcription of the IL-1β gene is controlled by the 
transcriptional activator NF-κB [10]. Therefore, to exam-
ine whether lysozyme fibrils activate the NF-κB pathway, 
we used a THP1 cell line stably transfected with a NF-κB 
reporter (THP1-XBlue cells). Figure 4b shows that incubation 
of THP1-XBlue cells with fibrillar aggregates of lysozyme 
led to the activation of NF-κB in a concentration-dependent 
manner (Fig. 4b, light grey). Lysozyme monomers and amor-
phous aggregates were again inactive (Fig. 4b, black and dark 
grey, respectively), even at the highest concentration tested.
As expected, NF-κB activation by lysozyme fibrils also 
leads to the secretion of high amounts of TNF-α, in a con-
centration-dependent manner, in non-primed THP1 cells 
(Fig. 4c) and primary BMDMs (Fig. 4f), while no TNF-α 
production was detected in the presence of lysozyme 
monomers and amorphous aggregates. Finally, incubation 
of THP1 cells with lysozyme fibrils in the presence of the 
NF-κB inhibitor Bay 11-7082 abolished TNF-α secretion 
(Fig. 4d), further confirming the role of NF-κB in generat-
ing the inflammasome priming signal.
Lysozyme fibrils are recognized by the TLR1/TLR2  
heterodimer
Figure 4 shows that fibrillar lysozyme activates the 
NF-κB pathway, but it is unclear which innate receptor 
is responsible for the sensing of fibrils. Toll-like recep-
tors (TLRs) are good candidates for this sensing as many 
signaling cascades initiated by these receptors lead to 
the activation of NF-κB. Therefore, we incubated THP1 
cells with lysozyme fibrillar aggregates in the presence of 
blocking antibodies raised against different TLRs. While 
neutralizing antibodies prevented the activation of TLR2, 
TLR4, and TLR5 by their respective ligands (Fig. 5a), 
only the anti-TLR2 antibody abrogated fibril-induced 
TNF-α secretion (Fig. 5b). Fibril signaling indeed remained 
unchanged in the presence of the anti-TLR4 and anti-TLR5 
antibodies, ruling out any involvement of TLR4 or TLR5 in 
fibril-sensing. This suggests that the induction of cytokine 
expression by lysozyme fibrils is mediated through TLR2.
Activation of NF-κB in TLR2-expressing HEK 293 cells 
(Materials and methods) by fibrillar lysozyme confirmed 
the role of this receptor in fibril detection (Fig. 5c, black 
bars), whereas lysozyme monomers or amorphous aggre-
gates (data not shown) did not activate these cells. TLR2 
signaling can be enhanced in the presence of CD14 [41], a 
glycoprotein involved in the recognition mechanism of sev-
eral TLR2 substrates. CD14 is not, however, required for the 
recognition of lysozyme fibrils, as no additional enhance-
ment in NF-κB activation was observed in HEK 293 cells 
expressing TLR2 and CD14 (Fig. 5c, grey bars). TLR4-
expressing HEK 293 cells did not show activation of NF-κB 
in response to fibrillar lysozyme (Fig. 5d), confirming that 
TLR4 is not implicated in the inflammatory cascade trig-
gered by lysozyme fibrils.
TLR2 functions as a heterodimer cooperating with TLR1 
to recognize triacetylated lipopeptides, or with TLR6 to 
sense diacetylated mycoplasmal lipopeptides [11]. To iden-
tify which receptor(s) TLR2 associates with in response to 
lysozyme amyloid fibrils, we used the neutralizing anti-
body strategy. Antibodies raised against TLR1 and TLR6 
prevented the activation of these receptors by their specific 
ligands (Fig. 5e). Whereas the anti-TLR6 antibody had 
only a moderate effect on the secretion of TNF-α induced 
by lysozyme fibrils, the anti-TLR1 antibody completely 
abolished this cytokine production (Fig. 5f). These results 
suggest that lysozyme fibrils are primarily sensed by the 
TLR2/TLR1 heterodimer, with TLR2/TLR6 playing a more 
minor role.
Discussion
Here, we show that lysozyme amyloid fibrils, but not 
non-fibrillar aggregates nor monomers, trigger caspase-
1-dependent processing of IL-1β through activation of 
the NLRP3 inflammasome in human cell lines and mouse 
primary macrophages. The NLRP3 inflammasome has 
been the most extensively studied NLR. One of the most 
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confusing aspects of its biology is that it is activated in 
response to a myriad of structurally unrelated compounds 
(for a review, see [42]), including muramyl dipeptide, bac-
terial toxins, extracellular ATP, skin irritants, particulate 
and crystalline substances such as asbestos fibers and silica 
particles, cholesterol, monosodium urate crystals, or sev-
eral amyloid aggregates [7, 9]. The precise mechanisms 
by which NLRP3 recognizes such a diverse range of sub-
stances is unclear, but it is likely to involve an intermediate 
factor common to different activators. Physical proper-
ties have been suggested to be the key for some classes of 
ligands [43, 44], as many present crystalline, aggregated, 
or particulate forms. Our data demonstrate that particulate 
structure alone is insufficient to activate NLRP3, as another 
aggregated state of lysozyme failed to induce inflamma-
tory responses. Literature reports other cases of particulate 
substances activating the NLRP3 inflammasome that loose 
this property when slightly modified. Morishige et al. [45] 
Fig. 4  Lysozyme fibrils induce IL-1β secretion from non-primed 
cells through NF-κB activation. a, c Unprimed THP1 cells were incu-
bated for 6 h with the indicated amounts of either lysozyme fibrils, 
monomers, or amorphous aggregates. IL-1β (a) and TNF-α (c) were 
quantified in the cell supernatants by ELISA; b THP1-XBlue cells 
were incubated for 6 h with the indicated amounts of either lysozyme 
fibrils (light grey), amorphous aggregates (dark grey), or mono-
mers (black). The phosphatase secreted upon NF-κB activation was 
detected using the Quanti Blue assay (Materials and methods); d 
THP1 cells were incubated for 6 h with 5 μM lysozyme fibrils, in the 
presence or absence of 20 μM of the NF-κB inhibitor Bay 11-7082. 
Cell supernatants were assayed for TNF-α by ELISA; e, f Unprimed 
primary BMDMs were stimulated for 21 h with the indicated 
amounts of either lysozyme fibrils, monomers, or amorphous aggre-
gates, or with LPS (100 ng/ml), and cell supernatants were analyzed 
for IL-1β (e) or TNF-α (f) by ELISA. n = 3, mean ± SD
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showed that silica particles, which are strong NLRP3 activa-
tors, become immunologically inactive when modified with 
specific functional groups, though the physical structure of 
these particles was unchanged. Polystyrene beads or diesel 
exhaust particles do not engage the NLRP3 inflammasome 
[46] despite their particulate nature. The characteristics of 
particulate substances required to activate NLRP3, however, 
remain to be clarified, but in the case of amyloid fibrils, our 
work present new evidence to propose that the key may 
reside in specific structural features.
Fig. 5  Lysozyme fibrils activate the TLR2/TLR1 heterodimer. a, b 
THP1 cells were incubated for 6 h with 1 ng/ml Pam3CSK4, 5 
ng/ml LPS, 100 ng/ml flagellin (a) or with 5 μM lysozyme fibrils 
(b), in the presence or absence of 20 μg/ml anti-TLR2, anti-TLR4, 
or anti-TLR5 antibodies. TNF-α was quantified in the cell superna-
tant by ELISA; c, d HEK 293 cells expressing TLR2 (c) or TLR4 and 
MD2 (d) with or without CD14 (grey and black bars, respectively) 
were incubated 6 h in the presence of Pam3CSK4 (10 ng/μl), LPS 
(100 ng/μl), or the indicated concentrations of either lysozyme mono-
mers or fibrils. NF-κB activation was detected by quantifying lucif-
erase activity in cell lysates; e, f THP1 cells were incubated for 6 h 
with 1 ng/ml Pam3CSK4, 100 ng/ml FSL-1, or with 5 μM lysozyme 
fibrils, in the presence or absence of 20 μg/ml anti-TLR2, anti-TLR1, 
or anti-TLR6 antibodies. TNF-α was quantified in the cell superna-
tants by ELISA. n = 3, mean ± SD
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Fibrils of other amyloidogenic proteins have been shown 
to trigger inflammasome cascades. Amyloid-β (Aβ) fibrils, 
whose extracellular accumulation in senile plaques is the 
hallmark of Alzheimer’s disease, induce the secretion of 
IL-1β through activation of the NLRP3 inflammasome [7]. 
Fibrillar aggregates of superoxide dismutase 1 (SOD1), the 
causative agent of amyotrophic lateral sclerosis (ALS), also 
trigger IL-1β secretion, although via a NLRP3-independent 
mechanism [13]. In both cases, the inflammatory prop-
erties have clearly been related to the fibrillar state of the 
protein. On the other hand, two recent works investigating 
the inflammatory properties of islet amyloid polypeptide 
(IAPP), whose fibrillar deposits are found in the pancreas 
of patients with type II diabetes, pointed oligomers as the 
immunologically active species [9, 14]. However, since 
aggregation of IAPP is extremely rapid [47, 48] and the 
presence of lipidic bilayers or cell membranes further accel-
erates this process [47, 49, 50], it is very difficult to identify 
precisely the entities responsible for cellular activation, and 
to know whether they contain cross-β structures. In contrast, 
the different species used in our work are stable. Fibrils and 
amorphous aggregates are end-products of aggregation, 
and WT lysozyme does not aggregate under physiological 
conditions.
Our results also demonstrate that amyloid fibrils induce 
the secretion of IL-1β from unprimed cells, implying that 
the aggregated protein could also accommodate the prim-
ing step through activation of a second pattern-recognition 
receptor (PRR), TLR2. In addition to provide inflamma-
some priming, TLR2 activation by lysozyme fibrils also 
leads to the secretion of many important inflammatory 
mediators, such as TNF-α, by activating the transcription 
factor NF-κB. The ability of amyloid fibrils to prime cells 
as well as drive inflammasome activity suggests a mecha-
nistic basis for the inflammatory pathogenesis associated 
with many amyloidoses. There is compelling evidence that 
TLR2 recognizes fibrils of other amyloidogenic proteins. 
The bacterial protein CsgA form fibrillar structures, called 
Curli fibrils, that mediate biofilm formation [51]. These 
bacterial fibrils activate TLR2, and the process proved to 
be fibril-specific [52]. Aβ fibrils trigger the expression of 
TNF-α through a mechanism involving activation of TLR2 
and TLR4, but non-fibrillar Aβ does not [52, 53].
How such large complexes are recognized by PRRs is 
unclear. It has recently been shown that TLR3 is able to rec-
ognized long double-stranded RNA through lateral cluster-
ing of TLR3 units along the length of the dsRNA ligand 
[54]. Fibril recognition by TLR2 could occur in a similar 
way along the fibril. Alternatively, small protein entities 
could break away from the fibril and bind the receptor, as 
observed for ultra-high weight polyethylene [55], or require 
an unidentified intermediary protein capable of extracting 
the appropriate species from the fibril. More studies are 
therefore required to understand the recognition mechanism 
of such large entities by innate immune receptors.
Finally, our results demonstrate that human lysozyme 
activates both TLR2 and NLRP3 when folded as amyloid 
fibrils, but fails to induce the same cascades when folded as 
monomers or as another type of aggregate. Consequently, 
we suggest that the inflammatory properties of lysozyme 
fibrils are related to their intrinsic structure. As explained 
above, fibrillar aggregates of other amyloidogenic proteins 
have been shown to activate TLR2 and/or NLRP3. Amy-
loidogenic proteins harbor different sequences and native 
structures, but present the same fibrillar character, with 
the typical cross-β structure [56], when they aggregate 
into fibrils. This structure can easily be detected with the 
specific ThT fluorescent probe [32]. Furthermore, amyloid 
fibrils cross-β structure is generally composed of parallel 
β-sheets, which can be detected using IR spectroscopy [25, 
26]. Unlike lysozyme fibrils, the immunologically inactive 
amorphous aggregates do not contain this characteristic 
structural motif, despite sharing the same sequence. They 
did not enhance ThT fluorescence, and their β-sheet content 
was only anti-parallel. Moreover, they were not detected by 
a conformation-dependent antibody specifically recognizing 
amyloid fibrils. On the basis of these results, it seems rea-
sonable to suggest that the immune system responds more 
specifically to several structural features of fibrils rather 
than to an aggregated state or to a specific sequence motif.
In conclusion, our work, combining structural and 
immunological data, clearly demonstrates that lysozyme 
fibrils are immunologically active species, and strongly sug-
gests that their cross-β sheet structure is critical for driving 
inflammatory responses to these aggregates. As a result, it 
is tempting to speculate that amyloid fibrils represent a new 
class of danger signals detected by the innate immune sys-
tem, through sensing of their common cross-β structure, a 
motif common to all amyloids irrespective of their origin 
[56]. Fibrils of microbial origin would indicate pathogen 
invasion, since amyloids are widely distributed among sev-
eral bacterium phyla [57], and would allow the immune sys-
tem to detect an ongoing infection, thus representing a new 
class of pathogen-associated molecular pattern. Fibrils of 
endogenous origin, arising from abnormal protein aggrega-
tion as in the case of amyloidogenic disorders, would warn 
the immune system of anomalous protein aggregation, thus 
constituting a new type of danger-associated molecular pat-
tern. Therefore, we propose that cross-β structure could be 
used by innate immunity as a generic pattern to detect exog-
enous as well as endogenous threats.
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